Expression patterns of CD180 in the lymph nodes of patients with chronic lymphocytic leukaemia

1. Gluckman E, Cappelli B, Bernaudin F, Labopin M, Volt F, Carreras J, et al. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation. Blood. 2017;129:1548–56. https://doi.org/10.1182/blood-2016-10-745711. 2. Foell J, Schulte JH, Pfirstinger B, Troeger A, Wolff D, Edinger M, et al. Haploidentical CD3 or a/b T-cell depleted HSCT in advanced stage sickle cell disease. Bone Marrow Transplant. 2019;54:1859–67. https://doi.org/10. 1038/s41409-019-0550-0. 3. Strocchio L, Zecca M, Comoli P, Mina T, Giorgiani G, Giraldi E, et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease. Br J Haematol. 2015;169:726–36. 4. Shenoy S, Eapen M, Panepinto JA, Logan BR, Wu J, Abraham A, et al. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016;128:2561–7. 5. Abraham A, Cluster A, Jacobsohn D, Delgado D, Hulbert ML, Kukadiya D, et al. Unrelated umbilical cord blood transplantation for sickle cell disease following reduced-intensity conditioning: results of a phase I trial. Biol Blood Marrow Transplant. 2017;23:1587–92. 6. de la Fuente J, Dhedin N, Koyama T, Bernaudin F, Kuentz M, Karnik L, et al. Haploidentical bone marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative. Biol Blood Marrow Transplant. 2019;25:1197– 209. 7. Gluckman E, Cappelli B, Scigliuolo GM, De la Fuente J, Corbacioglu S, et al. Alternative donor hematopoietic stem cell transplantation for sickle cell disease in Europe. Hematol Oncol Stem Cell Ther. 2020; 13:181–8. 8. Horowitz A, Djaoud Z, Nemat-Gorgani N, Blokhuis J, Hilton HG, B eziat V, et al. Class I HLA haplotypes form two schools that educate NK cells in different ways. Sci Immunol. 2016;1:eaag1672. 9. Ramsuran V, Naranbhai V, Horowitz A, Qi Y, Martin MP, Yuki Y, et al. Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells. Science. 2018;359:86–90. Erratum in: Science. 2019;365:eaay7985. 10. Braud VM, Allan DS, O’Callaghan CA, S€ oderstr€ om K, D’Andrea A, Ogg GS, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795–9. 11. Romagnani C, Pietra G, Falco M, Millo E, Mazzarino P, Biassoni R, et al. Identification of HLA-E-specific alloreactive T lymphocytes: a cell subset that undergoes preferential expansion in mixed lymphocyte culture and displays a broad cytolytic activity against allogeneic cells. Proc Natl Acad Sci USA. 2002;99:11328–33. 12. Merino AM, Sabbaj S, Easlick J, Goepfert P, Kaslow RA, Tang J, et al. Dimorphic HLA-B signal peptides differentially influence HLA-Eand natural killer cell-mediated cytolysis of HIV-1-infected target cells. Clin Exp Immunol. 2013;174:414–23. 13. Hallner A, Bernson E, Hussein BA, Ewald Sander F, Brune M, Aurelius J, et al. The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia. Blood. 2019;133:1479–88. 14. Petersdorf EW, Carrington M, O’hUigin C, Bengtsson M, De Santis D, Dubois V, et al. Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. Lancet Haematol. 2020;7:e50–e60. 15. Petersdorf EW, Gooley T, Volt F, Kenzey C, Madrigal A, McKallor C, et al. Use of the HLA-B leader to optimize cord-blood transplantation. Haematologica. 2020;Online ahead of print. https://doi.org/10.3324/haema tol.2020. 264424.